Preclinical Women Celmatix Therapeutics is a preclinical-stage biotech focused on women’s health with programs targeting ovarian aging, infertility, and endometriosis, indicating early-stage collaboration opportunities with partners in women's health, reproductive science, and clinical research.

ARPA-H Opportunity Recent engagement with ARPA-H and Sprint for Women's Health suggests potential co-development, funding-supported research, or contract research opportunities with government-backed initiatives and accelerated timelines.

Endometriosis Program The launch of a novel endometriosis drug program presents a pathway for partnerships in translational research, clinical CRO support, and market access strategies once preclinical milestones are reached.

AMHR2 Leadership AMHR2 agonist programme aiming to delay menopause signals opportunities for partnerships in biomarker development, ovarian biology expertise, and strategies around aging-related female health interventions.

Funding & Growth With funding of approximately 57M and a revenue range of 1M-10M, there is a potential for strategic alliances to scale: CRO networks, biobank collaborations, and pilot studies with payers or patient advocacy groups in women’s health.